Your browser doesn't support javascript.
Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.
Monserrat, Jorge; Gómez-Lahoz, Ana; Ortega, Miguel A; Sanz, José; Muñoz, Benjamin; Arévalo-Serrano, Juan; Rodríguez, José Miguel; Gasalla, Jose Maria; Gasulla, Óscar; Arranz, Alberto; Fortuny-Profitós, Jordi; Mazaira-Font, Ferran A; Teixidó Román, Miguel; Martínez-A, Carlos; Balomenos, Dimitri; Asunsolo, Angel; Álvarez-Mon, Melchor.
  • Monserrat J; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Gómez-Lahoz A; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
  • Ortega MA; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Sanz J; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
  • Muñoz B; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Arévalo-Serrano J; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
  • Rodríguez JM; Cancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.
  • Gasalla JM; Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.
  • Gasulla Ó; Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.
  • Arranz A; Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.
  • Fortuny-Profitós J; Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.
  • Mazaira-Font FA; Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.
  • Teixidó Román M; Hospital Universitari de Bellvitge, Universitat de Barcelona, 08907 L'Hospitalet de Llobregat, Spain.
  • Martínez-A C; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Balomenos D; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Asunsolo A; Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.
  • Álvarez-Mon M; Departament d'Econometria, Estadística I Economia Aplicada, Universitat de Barcelona, 08007 Barcelona, Spain.
  • On Behalf Of The Covid-Hupa Group; Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.
Int J Mol Sci ; 23(18)2022 Sep 07.
Article in English | MEDLINE | ID: covidwho-2010121
ABSTRACT
SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system-IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII-for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFß, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-27 / COVID-19 Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms231810344

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-27 / COVID-19 Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms231810344